Home » Newsletters » BioWorld Science

BioWorld Science

March 12, 2019

View Archived Issues

Secretome spills tumors' secrets

Hearing loss gene therapy works in adult mice

Dengue antibodies promote Zika-induced microcephaly

OKYO Pharma and collaborators report in vivo data for OKYO-0101 in dry eye murine model

Inflazome patents new NLRP3 inflammasome inhibitors

Boehringer Ingelheim presents promising data from proof-of-concept trial of BI-655130

AbbVie presents Mcl-1 inhibitors

Shanghai Ennova Biopharmaceutical identifies PD-1/PD-L1 interaction inhibitors

Allergan presents phase I/II results for bimatoprost sustained-release implants

Novel gene therapy prevents the onset of retinal degeneration in vivo

University of Toledo describes new HDAC inhibitors

Patient enrollment ongoing in phase II study of VRP-HER2 vaccine plus pembrolizumab

Promising interim data reported from first cohort of SUNRISE-PD study of AXO-Lenti-PD

ACADIA Pharmaceuticals divulges 5-HT2A receptor ligands

Extended evaluation phase findings from SONICS study of Recorlev in endogenous Cushing's syndrome

Characterization of novel negative allosteric modulators of metabotropic glutamate mGlu5 receptor

Steroidogenic 17beta-HSD2 inhibition for targeted intracrine therapy in bone fracture healing

Phase II results of TOL-463 for the treatment of bacterial vaginosis and vulvovaginal candidiasis

Mutations in TONSL, a fundamental DNA repair protein, cause SPONASTRIME dysplasia

Phase IIb FLUTE study of APT-1011 in eosinophilic esophagitis meets primary endpoint

Bridge Medicines signs agreement with Weill Cornell Medicine to develop novel S1P receptor modulator

CKAP4 unveiled as a new therapeutic target for PDAC

Phase III trials of vadadustat in Japanese patients with anemia due to CKD meet primary endpoint

Seres and AstraZeneca collaborate to study use of microbiome therapeutics in immuno-oncology

Axovant reports 3-month data on patient with infantile Tay-Sachs disease treated with AXO-AAV-GM2

FDA approves Dupixent for use in adolescents with moderate to severe atopic dermatitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...